Although the clinical onset of TTC seems to exhibit a preferred time of onset during morning hours and summer months, the number of patients considered in the studies is modest, and does not allow to draw definite conclusions. Thus, time of onset does not represent an useful tool in diagnosing TTC. In a clinical emergency setting, when a prompt differential diagnosis between AMI and TTC is needed, clinical factors (typical chest pain, female sex, postmenopausal age, recent stressful events) and instrumental examinations (electrocardiogram, transthoracic echocardiography) remain the first diagnostic tools. Ultimately, most patients require urgent coronary angiography to be sure that an acute thrombolysis is not the culprit. However, the identification of temporal frames characterized by highest frequency of onset, if confirmed on larger populations, could help for tailoring appropriate use of drugs, such as -blockers, to try to ensure maximal benefit for potentially at risk individuals during the particularly vulnerable periods.
Acute myocardial infarction and Tako-tsubo cardiomyopathy: could time of onset help to diagnose?
MANFREDINI, Roberto;
2011
Abstract
Although the clinical onset of TTC seems to exhibit a preferred time of onset during morning hours and summer months, the number of patients considered in the studies is modest, and does not allow to draw definite conclusions. Thus, time of onset does not represent an useful tool in diagnosing TTC. In a clinical emergency setting, when a prompt differential diagnosis between AMI and TTC is needed, clinical factors (typical chest pain, female sex, postmenopausal age, recent stressful events) and instrumental examinations (electrocardiogram, transthoracic echocardiography) remain the first diagnostic tools. Ultimately, most patients require urgent coronary angiography to be sure that an acute thrombolysis is not the culprit. However, the identification of temporal frames characterized by highest frequency of onset, if confirmed on larger populations, could help for tailoring appropriate use of drugs, such as -blockers, to try to ensure maximal benefit for potentially at risk individuals during the particularly vulnerable periods.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.